Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2013

Ascierto Paolo A, Minor David, Ribas Antoni, Lebbe Celeste, O'Hagan Anne, Arya Niki, Guckert Mary, Schadendorf Dirk, Kefford Richard F, Grob Jean-Jacques, Hamid Omid, Amaravadi Ravi, Simeone Ester, Wilhelm Tabea, Kim Kevin B, Long Georgina V, Martin Anne-Marie, Mazumdar Jolly, Goodman Vicki L, Trefzer Uwe

Abstract excerpt

PURPOSE: Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAF(V600E/K) mutation-positive metastatic melanoma (mut(+) MM). PATIENTS AND METHODS: Histologically confirmed pat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Melanoma

Share to Oximes

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Survival Rate

Source

Identifiers

PMID: 23918947
DOI: 10.1200/JCO.2013.49.8691

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23918947-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.PMID 23918947Read ↗

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Semantic proximity Read ↗

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.Semantic proximity Read ↗

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Semantic proximity Read ↗

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.Semantic proximity Read ↗

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.Semantic proximity Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.Semantic proximity Read ↗

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Semantic proximity Read ↗

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).Semantic proximity Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.